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Summary 
Regulation of macrophage scavenger receptor (MSR) activity may be an important determinant 
of the extent of atherogenesis.  The effect of macrophage-colony-stimulating factor (M-CSF) 
on this pathway was studied using a recently developed monoclonal antibody to murine MSR. 
M-CSF markedly and selectively increased MSR synthesis in murine macrophages: posttrans- 
lationally, the receptor appeared more stable and shifted to a predominantly surface distribution. 
Functionally,  M-CSF  enhanced modified lipoprotein uptake  and  increased  divalent cation- 
independent adhesion in vitro. These results  suggest a plausible  mechanism whereby M-CSF 
production in the atheromatous plaque microenvironment could promote the recruitment and 
retention of mononuclear phagocytes and subsequent foam cell formation. 
M  acrophages (MO) serve as the principal inflammatory 
. cell in the atheromatous plaque microenvironment. The 
macrophage scavenger receptor (MSR)  mediates modified 
lipoprotein-cholesterol uptake and subsequent cholesteryl ester 
accumulation and foam cell formation (1) and the regulation 
of MSR expression and activity therefore represents an im- 
portant determinant of the extent of atherogenesis. 
M-CSF treatment in patients with hematological disease 
coincides with significant reductions in serum cholesterol levels. 
As M-CSF enhances acetyhted low-density lipoprotein (AcLDL) 
uptake and degradation in human monocyte-derived  MO (2), 
the MSR pathway has been nonspecifically implicated in this 
observed reduction in serum cholesterol. Scavenger receptor 
activity is however also expressed by endothdiai, Kupffer, and 
liver parenchymal cells (3,  4) as well as by phorbol ester- 
induced fibroblasts  and smooth muscle cells (5). Molecules 
other than the macrophage-specific MSR may mediate these 
properties. Furthermore, other MO  receptors such as the 
thrombospondin receptor (CD36) and the IgG Fc receptor 
(Fc'/RII-B2; CD32) are capable of mediating uptake of oxi- 
dized lipoprotein (6,  7).  Characterization of MSR regula- 
tion and expression has been hampered by the lack of specific 
reagents. 
Both human and rabbit  atherosclerotic lesions  contain 
M-CSF mRNA and immunoreactive  M-CSF (8, 9). Vascular 
endothelial cells and smooth muscle cells produce M-CSF 
in response to a range of stimuli, including modified LDL 
(10). In addition, a novel function for the MSR as an adhe- 
sion receptor was recently described (11); this stemmed from 
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the observation that a mAb, 2F8,  to the murine MSR in- 
hibited divalent cation-independent MO adhesion in vitro, 
Using this MSR-specific reagent we show unequivocally that 
M-CSF markedly and selectively enhances MSR expression 
and function in murine-elicited peritoneal MO. 
Materials and Methods 
Isolation and Culture of Cells.  Elicited  peritoneal MO popula- 
tions were obtained from 5-7-wk-old Balb/c mice from this depart- 
ment by injecting Bio-Gel Pl00 polyacrylamide beads (Bio-Rad, 
Richmond, CA) (BgPM~3) 4-5 d before harvesting by sterile PBS 
peritoneal lavage. RPMI 1640 (GIBCO BRL, Paisley, UK) was 
supplemented  with 2 mM glutamine, 50 mg/ml streptomycin, 50 
IU/ml penicillin G, 20 mM Hepes (pH 7.3), and 10% FCS (Ad- 
vanced Protein Products, Brierley Hill, UK). 
Antibodies and Cytokines.  The following  primary rat mAbs were 
used: 2F8 (IgG2b, anti-MSR), F4/80 (IgG2b, anti-160 kD M(2) 
membrane antigen), 5C6 (IgG2b, anti-CR3), FA/11 (IgG2a, anti- 
macrosialin) (all from this laboratory); TIB120 (IgG2b, anti-class 
II MHC, from American  Type  Culture Collection, Rockville,  MD) 
and CAMPATH-1G (IgG2b, anti-human CDw52 but unreactive 
to murine antigens, provided by Dr. G. Hale, Cambridge Univer- 
sity, Cambridge, UK).  Neutralizing murine monoclonal anti- 
human M-CSF antibody 5H4 was from Dr. J. Schreurs (Chiron 
Corporation, Emeryville, CA) and goat anti-L cell M-CSF and 
M-CSF receptor antisera as well as rabbit anti-mouse macrophage 
mannose receptor (MMR) antiserum were from Drs. E. Richard 
Stanley  (Albert Einstein  College  of Medicine,  Bronx, NY) and Philip 
Stahl, (Washington University, St. Louis, MO) respectively. As 
second antibodies  the following  were used: goat anti-rat IgG (alka- 
line phosphatase-  and peroxidase-conjugated)  and rabbit anti-goat 
IgG (peroxidase-conjugated)  antisera from Sigma  Chemical  Co. (St. 
Louis, MO) and mouse anti-rat  IgG (FITC-conjugated F(ab')2) 
from Jackson ImmunoResearch Laboratories (West Grove, PA). 
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recombinant human M-CSF (1,000 U/m1) from Dr. S. Aukerman 
(Cetus Corp., Berkeley,  CA) is known to act on murine cells (12). 
Purified recombinant murine GM-CSF (1,000 U/ml) was a gift 
from Dr. A. Bernard  (Glaxo  Institute for Molecular  Biology,  Geneva, 
Switzerland). Murine M-CSF reagents used were either L cell con- 
ditioned medium (15% of RPMI 1640 incubation medium) as a 
rich source  of  murine M-CSF (13) or murine M-CSF  (=1,000 U/ml) 
as supematant from transfected insect cells obtained from Dr. J. 
Schreurs. 
Immunoblotting and Immunoprecipitation.  Cells  were plated at a 
density of 5  x  10+/well  in 35-mm tissue culture plastic dishes in 
KPMI plus 10% FCS and washed after 1-h incubation at 37~ 
Remaining adherent cells were treated with cytokines for 48 h. 
Metabolic labeling and immunoprecipitation was carried out as de- 
scribed (11). Protein concentrations of  lysates  were measured  using 
the bicinchoninic acid Protein Assay Reagent Kit (Pierce, Rock- 
ford, IL). Protein separation was by nonreducing (for immuno- 
blotting) or reducing (for immunoprecipitation)  5-10% linear gra- 
dient SDS-PAGE. Equal amounts of total cellular protein (20 tzg) 
were loaded. First, antibody was diluted to 10 #g/ml followed by 
incubation  with  peroxidase-conjugated anti-rat  IgG  antibody 
(1:1,000) and detection by chemiluminescence  (ECL; Amersham 
International, Amersham, Bucks, UK). 
Call surface distribution of MSK was investigated by labeling 
BgPMO overnight with 100 #Ci/ml Trans3SS-label  TM  (ICN Bio- 
chemicals, Irvine, CA). Cells were subsequently washed and sub- 
jected to surface  biotinylation using sulfo-NHS-SS-biotin  (Pierce) 
as described (14). Quantification of  protein bands on dried gels was 
by Phosphorlmager and ImageQuant software analysis program 
(Molecular Dynamics, Inc., Sunnyvale,  CA) and results expressed 
as a ratio of arbitrary PhosphorImager units (APUs). 
Flow Cytometry.  Cells  were stained with primary and FITC- 
conjugated  secondary  antibodies  before  flow cytometry (FACScan  | 
Becton Dickinson & Co., Mountain View, CA). Calls and debris 
having low forward scatter were routinely gated out of the anal- 
ysis. For visualization of intracdlular antigen, cells were permeabi- 
lized with 1% (wt/vol)  saponin in PBS with 1% FCS and 1% 
normal mouse serum (NMS) for 30 min. All subsequent steps were 
performed in the presence of 0.1% saponin in PBS with 1% FCS 
and 1% NMS. 
Reverse Transcription  (RT)-PCR Analysis.  Total  cellular  RNA was 
extracted with  KNAzol  solution  (Cinna/Biotex  Laboratories, 
Houston,  TX)  and reverse transcribed using  Moloney murine 
leukemia virus reverse transcriptase (BRL/GIBCO). The eDNA 
obtained served as a template for PCK using oligonucleotide pairs 
as follows: murine MSK (15) (a) common to both type I and II 
receptors (5' primer: 5'-CCAAGTCCTTGCAGAGTCTG-Y; Y- 
primer: 5'-GTCTGAGGTCGTTC~TGATG-Y; size of amplified 
fragment: 236 bp); (b) specific  for type I receptor (5' primer: 5'- 
ACCAACGACCTCAGACTGAA-Y;  3' primer: 5'-TAGACTCCG- 
GCAGACAACTT-Y;  size of  amplifaed  fragment: 431 bp); (c) specific 
for type II receptor (5' primer: 5'-TGGTGCTCCAGGAATAAG- 
AG-Y; 3' primer: 5'-GCATGACACAGGAACCAATG-Y;  size of 
amplified fragment: 342 bp) and murine/~-actin  (5' primer: 5'- 
TCAGAAGGACTCCTATGTGG-Y;  Y primer: 5'-GTACGACCA- 
GAGGCATACAG-Y;  size  of amplified  fragment: 299 bp). Ethidium 
bromide-stained PCK products were visualized  on a UV transiUu- 
minator after electrophoresis  on 2% agarose gels. Specificity  of the 
amplified bands was validated by their predicted size and restric- 
tion enzyme digests. Differences  in intensity of PCK bands were 
confirmed by 10-fold serial dilutions of eDNA samples to ensure 
comparability and that the plateau phase of amplification  had not 
been reached. The results shown are representative of three inde- 
pendent experiments. 
CellAdhesion  Assays.  BgPMO were cultured  in R.PMI  plus 10% 
FCS on tissue culture plastic (TCP) surfaces  in the presence or ab- 
sence of recombinant human M-CSF. Divalent cation-independent 
adhesion to TCP was assayed as described (11). 
Quantitation  of  AcLDL Uptake.  BgPMO in 24-well TCP plates 
(3  x  106 cells/well)  with M-CSF treatment  in triplicate  were exposed 
to 10 #g/ml AcLDL labeled  with DiI (1,1'-dioctadecyl-l-3,3,  3',3'- 
tetramethylindocarbocyanine perchlorate)  (Biogenesis, Bourne- 
mouth, UK). Uptake of DiIAcLDL was measured by flow cyto- 
metry as described (16). 
Results and Discussion 
To investigate the effects of M-CSF on MSR expression 
and function, we treated primary murine MO with recom- 
binant human M-CSF which is known to act on routine ceils 
(12). M-CSF treatment for 48 h markedly upregulated the 
expression of MSR protein on immunoblot analysis (Fig.  1, 
A  and/3). Recombinant murine GM-CSF, which decreases 
serum cholesterol to a lesser extent when infused as an ad- 
junct  to  chemotherapy (17), caused  a  noticeable,  but  less 
marked MSR increase (Fig.  1 B). To exclude effects due to 
growth factor-induced proliferation, loading of lysates per 
well was corrected for total cellular protein concentration. 
In addition, it has previously been shown that M-CSF treat- 
ment of  human monocyte-derived  M(3 increases  cell size rather 
than cell number (2). The observed increase in MSR protein 
would therefore be even more significant at a single cell level. 
Conditioned media from mouse L cells (a rich source of mu- 
rine  M-CSF  [13]) or insect cells  transfected with murine 
M-CSF eDNA similarly increased MSR expression,  and this 
effect was abrogated by the addition of species-specific anti- 
bodies to M-CSF (data not shown). The increase  in MSK 
expression  was dose dependent and plateaued at concentra- 
tions of 500-1,000  U/ml M-CSF (data not shown). 
Immunoprecipitation of MSR from metabolically labeled 
cells confirmed the upregulation  by M-cAr (Fig. 2). The mAb 
2F8 detects both type I and II isoforms of the MSK (11) and 
the MSR is seen in its reduced monomeric form. M-CSF 
increased MSK protein synthesis 2.3-fold (Phosphorlmager 
quantification) even after 48 h of  treatment, as is evident from 
Figure  1.  M-CSF  increases  MSK pro- 
tein expression.  For immunoblot  analysis 
with mAb 2F8, BgPMO  were  treated  for 
48 h with human  M-CSF (1,000 U/ml) 
and  murine GM-CSF (1,000 U/ml). 
Results (A and B) are from  two indepen- 
dent experiments. (4) 200-kD marker. 
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impressive increases seen at  12 (4.5-fold)  and 36 h  (6-fold) 
signify that, in addition to increasing MSR synthesis, M-CSF 
also markedly prolonged the half-life of synthesized receptor. 
Expression of MSR at a single cell level as determined by 
flow cytometry (Table 1 A) confirmed that M-CSF upregu- 
lated MO cell surface expression of the receptor. The greater 
than twofold increase in MSR surface expression was not par- 
allded by the more modest 18% increase seen when intracel- 
lular (internal) levels  of antigen were assessed  by permeabilizing 
the cells with saponin. It was therefore possible that M-CSF 
may have redistributed the substantial intracdlular pool of 
MSR to the cell surface. Indirect immunofluorescence  studies 
with the mAb 2F8, although difficult to quantify, supported 
this hypothesis (data  not shown). It is interesting to note 
that GM-CSF had little effect on surface or internal MSR 
expression  as assessed by flow cytometry, in keeping with 
the slight increase  seen by immunoblotting. 
The possible redistributive effect of M-CSF was investigated 
by biochemically quantifying the fraction of total MSR on 
the cell surface at steady state (Table 1 B). Cells were meta- 
bolically labeled to equilibrium foUowed by surface biotiny- 
lation, on ice, by the membrane-impermeant  probe sulfo-NHS- 
SS-biotin  (14). After cell lysis, total MSR was precipitated 
by mAb 2F8 and the resulting immunoprecipitate divided 
into two equal aliquots. Biotinylated "surface"  MSR was 
precipitated from one aliquot using streptavidin-agarose  and 
"total" MSR was precipitated from the other aliquot by a 
second round of mAb 2F8 immunoprecipitation. Total and 
biotinylated MSR were quantitated after SDS-PAGE by Phos- 
phorlmager analysis of dried gels. In these experiments M-CSF 
increased surface MSR expression 13-fold and total MSR pro- 
tein synthesis nearly 5-fold relative to untreated controls. In 
addition, M-CSF treatment was associated with a shift of 
the cellular pool of MSR from a mainly intraceUular loca- 
tion (69% of total) to a predominantly surface distribution 
(82%  of total). 
To exclude the possibility that the M-CSF effect on MSR 
expression represented a nonselective epiphenomenon  of MO 
differentiation, we analyzed the action of M-CSF on several 
other MO integral membrane proteins (Table 1 B). The ex- 
Table  1.  M-CSF Selectively Increases MSR  Surface Expression 
A  Treatment  Surface  Internal 
Control  100  100 
M-CSF  232  118 
GM-CSF  81  107 
B  Treatment  Total  Surface 
Control  23,100  7,100 
Percent  surface/total  31% 
M-CSF  115,400  94,900 
Percent  surface/total  82% 
C 
Treatment 
Surface  Internal 
Control  M-CSF  Control  M-CSF 
MSR  60  117  177  208 
F4/80  antigen  221  212  325  343 
CR3  281  324  509  416 
Class  IIMHC  43  36  44  41 
Macrosialin  39  26  257  182 
Figure 2.  M-CSF increases  MSR protein synthesis. BgPM~) were treated 
in vitro for 48 h with human M-CSF (1,000 U/ml), metabolically  labeled 
with Tran3SS-label  TM and chased for the indicated periods. Pr~pitates were 
adjusted to represent equivalent total protein concentrations,  and separated 
by SDS-PAGE in the presence of B-ME.  MSR precursor and monomer 
migrate at ~  and 90 Fa:l,  respectively. Gels were fixed, impregnated with 
EN3HANCE,  dried,  and  exposed  to  film at  -70~  (')  Molecular 
weight standards  in kilodaltons. 
(/1) Effect of M-CSF and GM-CSF on expression of MSR by flow cytom- 
etry. BgPMO were treated in vitro for 48 h as indicated and stained with 
either mAb 2F8 or CAMPATH-1G plus FITC-eonjugated second anti- 
body before flow cytometry. Results are depicted as percentage of con- 
trol values and are the means of three experiments (each experiment in 
triplicate) in which specific fluorescence intensities were determined by 
subtracting geometric mean fluorescence obtained with CAMPATH-1G 
from that obtained with mAb 2F8. (B) Effect of M-CSF on cell surface 
distribution of MSR. BgPMO were metabolically  labeled and surface bi- 
otinylated using sulfo-NHS-SS-biotin. Quantification of protein bands 
on dried gels was done by Phosphorlmager and results expressed  as a 
ratio of arbitrary APUs.  (C)  Effect  of M-CSF on expression of MO 
differentiation antigens by flow cytometry. BgPM~ were stained with 
the indicated mAb or its isotype control plus FITC-conjugated second 
antibody before analysis by flow cytometry. The specific mAbs used were 
F4/80,  5C6  (CR3),  TIB120  (class II M/-/C), and FA-11 (macrosialin). 
Results show the mean values (single experiment in triplicate) of specific 
fluorescence intensities determined by subtracting  geometric mean fluores- 
cence obtained with the isotype control from that obtained with the spe- 
cific mAb. 
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differentiation antigen), type 3 complement receptor, MHC 
class II antigen and macrosialin (a M~-speciiic late endosomal 
membrane molecule) were analyzed  by flow cytometry. M-CSF 
treatment elicited slight increases only in surface CR3 (15%) 
and internal F4/80 (6%) levels. The other antigens were ei- 
ther unchanged or decreased. Immnnoblots of M-CSF treated 
BgPM~ also showed no alteration in expression  of MMR 
or class II MHC (data  not shown). These results point to 
a selective effect of M-CSF on MSR expression in an elicited 
primary M~  population. 
The point at which M-CSF mediates its upregulatory effect 
was investigated by semi-quantitative RT-PCR to detect MSR 
mRNA changes in response to M-CSF (Fig. 3). This assay 
provides a sensitive measure of mRNA in M(3, and control 
serial dilution experiments confirmed that for each  set of 
primers the level of detection could be related to the initial 
cellular input used to prepare the cDNA. Two isoforms of 
MSR arise from alternative splicing of transcripts derived from 
a single gene. Both isoforms have been detected in athero- 
sclerotic lesions and bind MSR ligands with equal affinities 
(18, 19). After M-CSF treatment for 48 h, there was a sub- 
stantial increase in MSR mRNA (MSR-C). In addition, levels 
of mRNA specific for both type I and II MSR mRNA were 
increased,  excluding a type-selective  effect for M-CSE  Al- 
though type I MSR mRNA was present in untreated cells, 
type II MSR protein is more prevalent in vivo and in vitro 
(15). Detection of type I message in the control cells could, 
however, be explained by increased annealing affinity of the 
specific set of primers for the cDNA template. Similar results 
were obtained after  24  h  of M-CSF incubation (data  not 
shown). M-CSF therefore also upregulates MSR expression 
at mRNA level. Whether this is due to transcriptional up- 
regulation or posttranscriptional stabilization  was not ad- 
dressed. 
As described, M-CSF increased MSR expression at several 
different levels: message, protein synthesis, protein stability, 
and shift of mature protein to the cell surface. The significance 
of these observed differences was tested by relating them to 
functional MSR studies.  Traditionally,  the MSR has been 
characterized as an endocytic receptor (20) with a broad ligand- 
binding  specificity  for  a  range  of polyanions  (including 
modified  lipoproteins). The ability of treated BgPMt~ to en- 
docytose and accumulate fluorescent  AcLDL (DiI-AcLDL) 
was therefore tested (Table 2).  M-CSF-mediated upregula- 
tion of routine MSR was associated with an enhanced ca- 
pacity (1.7-3-fold)  of treated M~  to endocytose AcLDL. 
AcLDL uptake is regarded as a specific marker for MSR func- 
tion, as the thrombospondin receptor (CD36) and the Mt~ 
receptor for the Fc region of IgG (Fc3~RII-B2; CD32) may 
mediate uptake of oxidized but not acetylated  lipoprotein 
(6, 7). 
A recently described novel function for the MSR is diva- 
lent cation-independent adhesion (11). The ability of M-CSF- 
treated BgPM(3 to adhere to serum-treated TCP in an EDTA- 
independent manner was investigated. M-CSF increased adhe- 
sion at 60 min by 63%  and at 90 min by 96%; this effect 
was completely abolished in the presence of mAb 2F8 (data 
not shown). The adherence of M-CSF-treated M~ in vitro 
was therefore markedly increased in a MSR-dependent (diva- 
lent cation-independent, 2F8-inhibitable)  fashion. 
Atherogenesis is characterized by both the proliferation of 
smooth muscle cells, M~, and lymphocytes  in the artery wall 
and the accumulation of cholesterol and cholesteryl esters in 
the surrounding connective tissue matrix and associated cells. 
Besides acting as a growth factor for the proliferation and 
differentiation of monocytic progenitors, M-CSF is also re- 
quired for the survival and activation of mature monocytes 
and M~ (21). The LDL receptor is primarily responsible for 
regulating plasma LDL  homeostasis and LDL-cholesterol 
delivery to tissue and cells by clearing plasma-derived LDL- 
cholesterol.  Hepatic LDL receptor function, as assayed by 
LDL binding, is however not markedly affected by M-CSF 
treatment. GM-CSF had a minimal effect on MSR activity 
and its cholesterol lowering effect could be mediated indirectly 
through stimulation of TNF and/or IL-1 secretion (22). In 
contrast, our evidence shows that M-CSF significantly  en- 
hances MSR expression and function in vitro. This provides 
a mechanism whereby production of M-CSF in the atheroma- 
tous plaque microenvironment  could enhance the recruitment 
and retention of mononuclear phagocytes and subsequent ac- 
cumulation of cholesteryl esters and foam cell formation. 
Table  2.  M-CSF  Increases the Uptake of DiI-AcLDL by BgPM~ 
Treatment  Expt.  1  Expt.  2  Expt.  3 
Control  314  _+  15  239  _+  14  166  +  17 
M-CSF  541  +_  17  496  +  34  492  _+  32 
Percent increase  172%  208%  297% 
Figure  3.  M-CSF increases both type I and II MSR mlLNA. BgPM~) 
were incubated with M-CSF for 24 and 48 h. RT-PCR was done as de- 
scribed in Materials and Methods.  MSR-C represents transcripts common 
to both type I and II MSR. The results shown are representative of three 
independent  experiments. 
BgPMO were treated for 48 h with human M-CSF and MSR-mediated 
uptake  of DilAcLDL measured as described (11,16).  Specific fluorescent 
intensity was  calculated by subtracting  autofluorescent  intensity from 
fluorescent  intensity of DiIAcLDL-labeled cells using geometric means 
derived from data analysis by Lysys II software (Bee'ton  Dickinson). Results 
show the mean values  _+  standard  deviation (three independent  experi- 
ments  in triplicate). 
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